Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abycet versus Erbitux in TPEx-treated head and neck squamous cell carcinoma
IRCT20211218053442N2Phase 3Completed
- Sponsor
- Zistdaru Danesh
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Zistdaru Danesh. Primary endpoint: Disease Control Rate. Started Jan 2025; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on IRCT20211218053442N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211218053442N2.